OVERVIEW

Amid the coronavirus pandemic, the global market size for drug safety and pharmacovigilance software is set to grow at a CAGR of 6.52% during the forecast period. The growth of the global pharmacovigilance and drug safety software market is driven by factors such as the incidence rates of adverse drug reactions (ADRs) and growing adoption of pharmacovigilance software by outsourcing companies. The report discusses in detail the impact of COVID-19 on market for the year 2020 and beyond.

TABLE OF CONTENT

• 2 RESEARCH METHODOLOGY
  • 2.1 Research Data
    • 2.1.1 Secondary Data
      • 2.1.1.1 Key Data From Secondary Sources
    • 2.1.2 Primary Data
      • 2.1.2.1 Key Data From Primary Sources
      • 2.1.2.2 Key Industry Insights
      • 2.1.2.3 Breakdown of Primaries
  • 2.2 Market Size Estimation
    • 2.2.1 Bottom-Up Approach
    • 2.2.2 Top-Down Approach
  • 2.3 Market Breakdown and Data Triangulation
  • 2.4 Research Assumptions

• 3? Executive Summary
  • 3.1 Market Revenue, Market Size and Key Trends by Company
  • 3.2 Key Trends by type of Application
  • 3.3 Key Trends segmented by Geography

• 4 Comparative Analysis
  • 4.1 Product Benchmarking - Top 10 companies
  • 4.2 Top 5 Financials Analysis
  • 4.3 Market Value split by Top 10 companies
  • 4.4 Patent Analysis - Top 10 companies
  • 4.5 Pricing Analysis

• 5 Industry Market Entry Scenario
  • 5.1 Regulatory Framework Overview
  • 5.2 New Business and Ease of Doing business index
  • 5.3 Case studies of successful ventures
  • 5.4 Customer Analysis ? Top 10 companies

• 6 Global Drug Safety and Pharmacovigilance Software Market - Market Forces
  • 6.1 Introduction
  • 6.2 Market Dynamics
    • 6.2.1 Drivers
    • 6.2.2 Opportunities
    • 6.2.3 Challenges
  • 6.3 Porters Analysis of Market
    • 6.3.1 Bargaining power of suppliers
    • 6.3.2 Bargaining powers of customers
    • 6.3.3 Threat of new entrants
    • 6.3.4 Rivalry among existing players
    • 6.3.5 Threat of substitutes

• 7 Global Drug Safety and Pharmacovigilance Software Market - Strategic Analysis
  • 7.1 Value Chain analysis
  • 7.2 Product Life Cycle
  • 7.3 Supplier and distributor analysis (Market share and product dealing strategies)

• 8 Global Drug Safety and Pharmacovigilance Software Market ? By Functionality (Market Size ?

• • 8.1 Adverse Event Reporting Software
  • 8.2 Drug Safety Audits Software
  • 8.3 Issue Tracking Software
  • 8.4 Fully Integrated Software

• 9 Global Drug Safety and Pharmacovigilance Software Market - By Delivery Mode
  • 9.1 On-premise Delivery Mode
  • 9.2 On-demand/Cloud based (SaaS) Delivery Mode

• 10 Global Drug Safety and Pharmacovigilance Software Market - By End-User
  • 10.1 Pharma and Biotech Companies
  • 10.2 Contract Research Organizations (CROs)
  • 10.3 Business Process Outsourcing (BPO) Firms
  • 10.4 Other

• 11 Global Drug Safety and Pharmacovigilance Software Market ? By Geography (Market Size

• • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 U.K
    • 11.3.2 Germany
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia-Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 South Korea
    • 11.4.5 Rest of APAC
  • 11.5 Rest of the World
    • 11.5.1 South America
    • 11.5.2 Middle East
    • 11.5.3 Africa

• 12 Global Drug Safety and Pharmacovigilance Software Market ? Entropy
  • 12.1 New product launches
  • 12.2 M&A's, collaborations, JVs and partnerships

• 13 Global Drug Safety and Pharmacovigilance Software Market Company Profile (Key Players)
  • 13.1 Market Share, Company Revenue, Products, M&A, Developments
  • 13.2 AB-Cube
  • 13.3 Arisglobal
  • 13.4 Sparta Systems, Inc
  • 13.5 United Biosource Corporation
  • 13.6 Umbra Global
  • 13.7 Extedo GMBH.
  • 13.8 Ennov.
  • 13.9 Online Business Applications, Inc
  • 13.10 Oracle Corporation.
  • 13.11 Sarjen Systems Pvt. Ltd
  • 13.12 Company 11 & more

• 14 Global Drug Safety and Pharmacovigilance Software Market - Appendix
  • 14.1 Sources
  • 14.2 Abbreviations